StreetInsider.com News Articles

Form 8-K BioNexus Gene Lab Corp For: Feb 23

Mon, 23 Feb 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260223/26039950.html

Form 8-K BioNexus Gene Lab Corp For: Feb 23

Mon, 23 Feb 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260223/26039950.html

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Mon, 23 Feb 2026 08:30:00 -0400

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. (“Chemrex”).

As part of this restructuring, Chemrex’s board has been streamlined to two directors:

Matthew L. Barsing, Chairman
Angeline Chong, Chief Financial Officer of BioNexus, Director

New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Mon, 23 Feb 2026 08:30:00 -0400

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework

As part of this restructuring, Chemrex’s board has been streamlined to two directors:

Matthew L. Barsing, Chairman
Angeline Chong, Chief Financial Officer of BioNexus, Director

New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Mon, 23 Feb 2026 08:30:00 -0400

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework

As part of this restructuring, Chemrex’s board has been streamlined to two directors:

Matthew L. Barsing, Chairman
Angeline Chong, Chief Financial Officer of BioNexus, Director

New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Mon, 23 Feb 2026 08:30:00 -0400

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework

As part of this restructuring, Chemrex’s board has been streamlined to two directors:

Matthew L. Barsing, Chairman
Angeline Chong, Chief Financial Officer of BioNexus, Director

New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private

Form 8-K BioNexus Gene Lab Corp For: Jan 28

Tue, 03 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260203/25938794.html

Form 8-K BioNexus Gene Lab Corp For: Jan 28

Tue, 03 Feb 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260203/25938794.html

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

Wed, 28 Jan 2026 09:00:00 -0400

KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026.

The Economic Imperative: Shattering the $3,000 Barrier
Current liquid

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

Wed, 28 Jan 2026 09:00:00 -0400

The Economic Imperative: Shattering the $3,000 Barrier
Current liquid

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

Wed, 28 Jan 2026 09:00:00 -0400

The Economic Imperative: Shattering the $3,000 Barrier
Current liquid

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

Wed, 28 Jan 2026 09:00:00 -0400

The Economic Imperative: Shattering the $3,000 Barrier
Current liquid

Form 8-K BioNexus Gene Lab Corp For: Dec 24

Tue, 30 Dec 2025 13:31:00 -0400

si-local-file:///var/storage/secattach/20251230/25789969.html

Form 8-K BioNexus Gene Lab Corp For: Dec 24

Tue, 30 Dec 2025 13:31:00 -0400

si-local-file:///var/storage/secattach/20251230/25789969.html

Form 8-K BioNexus Gene Lab Corp For: Dec 19

Tue, 23 Dec 2025 17:20:00 -0400

si-local-file:///var/storage/secattach/20251223/25778130.html

Form 8-K BioNexus Gene Lab Corp For: Dec 19

Tue, 23 Dec 2025 17:20:00 -0400

si-local-file:///var/storage/secattach/20251223/25778130.html

Form DEF 14A BioNexus Gene Lab Corp For: Dec 24

Wed, 03 Dec 2025 17:15:00 -0400

si-local-file:///var/storage/secattach/20251203/25696478.html

Form DEF 14A BioNexus Gene Lab Corp For: Dec 24

Wed, 03 Dec 2025 17:15:00 -0400

si-local-file:///var/storage/secattach/20251203/25696478.html

BioNexus completes investment in Fidelion, gains 15% stake and Asia rights

Wed, 03 Dec 2025 08:45:11 -0400

BioNexus Gene Lab Corp. (NASDAQ: BGLC) completed a strategic transaction with Fidelion Diagnostics Pte. Ltd., acquiring a 15% equity stake in the company and exclusive commercial rights for the VitaGuard™ liquid biopsy platform across Southeast Asia.

The biotechnology company obtained the equity position through a share exchange, while Fidelion received approximately 16.6% of BioNexus's outstanding stock. The transaction provides BioNexus with exclusive, perpetual rights to manufacture, market and distribute VitaGuard™ across all ASEAN markets.

VitaGuard™ is an AI-enabled platform designed for tumor-naïve minimal residual disease monitoring through liquid biopsy technology. The system enables detection of early cancer recurrence signs and supports treatment

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

Wed, 03 Dec 2025 08:45:00 -0400

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology.

With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across Southeast Asia (ASEAN) — positioning the Company for long-term growth as precision oncology adoption accelerates across the region.

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

Wed, 03 Dec 2025 08:45:00 -0400

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

Wed, 03 Dec 2025 08:45:00 -0400

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

Wed, 03 Dec 2025 08:45:00 -0400

BioNexus Gene Lab secures $500 million equity facility from ARC Group

Tue, 02 Dec 2025 08:06:25 -0400

BioNexus Gene Lab Corp. (NASDAQ: BGLC) announced it has entered into a $500 million equity purchase agreement with ARC Group International Ltd., providing the company with discretionary access to capital over 36 months.

Under the agreement, BioNexus Gene Lab may issue and sell registered shares of its common stock to ARC at its sole discretion. The company issued 175,000 shares as a one-time fee, priced at $4.32 per share based on the November 26 closing price. ARC is restricted from owning more than 9.99% of outstanding shares and is prohibited from short-selling or hedging the company's securities.

The facility complements the company's

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercializati

Tue, 02 Dec 2025 08:05:00 -0400

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the “Facility”) with ARC Group International Ltd. (“ARC”), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard™ minimal residual disease (MRD) platform, the addition of contract